Artemisinin is an antimalarial agent with anticancer activity. It is an iron(II) oxide-reactive endoperoxide that generates reactive oxygen species (ROS) upon cleavage of its endoperoxide bridge. It reduces the growth of various P. falciparum strains in vitro (IC50s = 3.98-20.36 nM) and reduces parasitemia in mice infected with P. falciparum with a curative dose (CD50) value of 140 mg/kg. It also reduces P. berghei infection in mice (ED50 = 5.6 mg/kg per day).

CHEMICAL PROPERTIES

SAFETY INFORMATION

PRODUCT USAGE

Artemisinin, a sesquiterpene lactone extracted from the sweet wormwood plant (Artemisia annua), is globally recognized as the most effective treatment for malaria. Its primary application is in the pharmaceutical industry, where it serves as the core active ingredient in Artemisinin-based Combination Therapies (ACTs), the World Health Organization's gold standard for treating multi-drug resistant malaria. Beyond its antimalarial role, it is increasingly utilized in biomedical research for its promising anti-tumor activities, specifically its ability to induce apoptosis in various cancer cell lines. In the nutraceutical sector, artemisinin is featured in specialized dietary supplements aimed at supporting immune function and addressing parasitic imbalances. Furthermore, it acts as a critical chemical precursor for the semi-synthesis of potent derivatives like artemether and artesunate, which offer improved solubility and bioavailability for clinical use.